Brief: Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy

Intra-Cellular Therapies

03/12/2024 12:43

Dec 3 (Reuters) - Intra-Cellular Therapies Inc  ITCI.O :
    * INTRA-CELLULAR THERAPIES SUBMITS SUPPLEMENTAL NEW DRUG
APPLICATION (SNDA) TO FDA FOR CAPLYTA® (LUMATEPERONE) FOR THE
TREATMENT OF MAJOR DEPRESSIVE DISORDER AS ADJUNCTIVE THERAPY

Source text:  ID:nGNXjhYRX 
Further company coverage:  ITCI.O 

 ((Reuters.Briefs@thomsonreuters.com;))